Varghese Finny S, Thaa Bastian, Amrun Siti Naqiah, Simarmata Diane, Rausalu Kai, Nyman Tuula A, Merits Andres, McInerney Gerald M, Ng Lisa F P, Ahola Tero
Department of Food and Environmental Sciences, University of Helsinki, Helsinki, Finland
Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
J Virol. 2016 Oct 14;90(21):9743-9757. doi: 10.1128/JVI.01382-16. Print 2016 Nov 1.
Chikungunya virus (CHIKV) has infected millions of people in the tropical and subtropical regions since its reemergence in the last decade. We recently identified the nontoxic plant alkaloid berberine as an antiviral substance against CHIKV in a high-throughput screen. Here, we show that berberine is effective in multiple cell types against a variety of CHIKV strains, also at a high multiplicity of infection, consolidating the potential of berberine as an antiviral drug. We excluded any effect of this compound on virus entry or on the activity of the viral replicase. A human phosphokinase array revealed that CHIKV infection specifically activated the major mitogen-activated protein kinase (MAPK) signaling pathways extracellular signal-related kinase (ERK), p38 and c-Jun NH-terminal kinase (JNK). Upon treatment with berberine, this virus-induced MAPK activation was markedly reduced. Subsequent analyses with specific inhibitors of these kinases indicated that the ERK and JNK signaling cascades are important for the generation of progeny virions. In contrast to specific MAPK inhibitors, berberine lowered virus-induced activation of all major MAPK pathways and resulted in a stronger reduction in viral titers. Further, we assessed the in vivo efficacy of berberine in a mouse model and measured a significant reduction of CHIKV-induced inflammatory disease. In summary, we demonstrate the efficacy of berberine as a drug against CHIKV and highlight the importance of the MAPK signaling pathways in the alphavirus infectious cycle.
Chikungunya virus (CHIKV) is a mosquito-borne virus that causes severe and persistent muscle and joint pain and has recently spread to the Americas. No licensed drug exists to counter this virus. In this study, we report that the alkaloid berberine is antiviral against different CHIKV strains and in multiple human cell lines. We demonstrate that berberine collectively reduced the virus-induced activation of cellular mitogen-activated protein kinase signaling. The relevance of these signaling cascades in the viral life cycle was emphasized by specific inhibitors of these kinase pathways, which decreased the production of progeny virions. Berberine significantly reduced CHIKV-induced inflammatory disease in a mouse model, demonstrating efficacy of the drug in vivo Overall, this work makes a strong case for pursuing berberine as a potential anti-CHIKV therapeutic compound and for exploring the MAPK signaling pathways as antiviral targets against alphavirus infections.
自十年前再次出现以来,基孔肯雅病毒(CHIKV)已在热带和亚热带地区感染了数百万人。我们最近在一次高通量筛选中确定无毒植物生物碱小檗碱是一种抗CHIKV的抗病毒物质。在此,我们表明小檗碱在多种细胞类型中对多种CHIKV毒株有效,即使在高感染复数时也是如此,巩固了小檗碱作为抗病毒药物的潜力。我们排除了该化合物对病毒进入或病毒复制酶活性的任何影响。一项人类磷酸激酶阵列显示,CHIKV感染特异性激活了主要的丝裂原活化蛋白激酶(MAPK)信号通路,即细胞外信号调节激酶(ERK)、p38和c-Jun氨基末端激酶(JNK)。在用小檗碱处理后,这种病毒诱导的MAPK激活明显降低。随后用这些激酶的特异性抑制剂进行的分析表明,ERK和JNK信号级联对于子代病毒粒子的产生很重要。与特异性MAPK抑制剂不同,小檗碱降低了病毒诱导的所有主要MAPK通路的激活,并导致病毒滴度有更强的降低。此外,我们在小鼠模型中评估了小檗碱的体内疗效,测量到CHIKV诱导的炎症性疾病有显著减轻。总之,我们证明了小檗碱作为抗CHIKV药物的疗效,并强调了MAPK信号通路在甲病毒感染周期中的重要性。
基孔肯雅病毒(CHIKV)是一种蚊媒病毒,可引起严重且持续的肌肉和关节疼痛,最近已传播到美洲。目前没有用于对抗这种病毒的许可药物。在本研究中,我们报告生物碱小檗碱对不同的CHIKV毒株和多种人类细胞系具有抗病毒作用。我们证明小檗碱总体上降低了病毒诱导的细胞丝裂原活化蛋白激酶信号的激活。这些激酶途径的特异性抑制剂强调了这些信号级联在病毒生命周期中的相关性,这些抑制剂减少了子代病毒粒子的产生。小檗碱在小鼠模型中显著减轻了CHIKV诱导的炎症性疾病,证明了该药物在体内的疗效。总体而言,这项工作有力地支持了将小檗碱作为一种潜在的抗CHIKV治疗化合物来研究,并将MAPK信号通路作为抗甲病毒感染的抗病毒靶点来探索。